| __timestamp | BeiGene, Ltd. | Bio-Techne Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 6930000 | 60716000 |
| Thursday, January 1, 2015 | 7311000 | 119401000 |
| Friday, January 1, 2016 | 20097000 | 140879000 |
| Sunday, January 1, 2017 | 62602000 | 199243000 |
| Monday, January 1, 2018 | 195385000 | 240636000 |
| Tuesday, January 1, 2019 | 388249000 | 264359000 |
| Wednesday, January 1, 2020 | 600176000 | 260583000 |
| Friday, January 1, 2021 | 990123000 | 324951000 |
| Saturday, January 1, 2022 | 1277852000 | 372766000 |
| Sunday, January 1, 2023 | 1504501000 | 378378000 |
| Monday, January 1, 2024 | 396826000 |
In pursuit of knowledge
In the ever-evolving world of biotechnology, understanding the financial dynamics of industry leaders is crucial. Over the past decade, BeiGene, Ltd. and Bio-Techne Corporation have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, BeiGene's SG&A costs skyrocketed by over 21,000%, reflecting its aggressive expansion and investment strategies. In contrast, Bio-Techne's expenses grew by a modest 523%, indicating a more stable growth trajectory.
By 2023, BeiGene's SG&A expenses reached a peak, nearly quadrupling Bio-Techne's, highlighting its rapid scaling efforts. However, the data for 2024 is incomplete, leaving room for speculation on future trends. This financial narrative not only underscores the strategic differences between these two biotech powerhouses but also offers insights into their operational priorities and market positioning.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Bio-Techne Corporation
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Comparing SG&A Expenses: BeiGene, Ltd. vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and CRISPR Therapeutics AG
Selling, General, and Administrative Costs: BeiGene, Ltd. vs MannKind Corporation
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Geron Corporation
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Bio-Techne Corporation vs Rhythm Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Bio-Techne Corporation or Bausch Health Companies Inc.
Breaking Down SG&A Expenses: Bio-Techne Corporation vs Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Bio-Techne Corporation or Taro Pharmaceutical Industries Ltd.
Selling, General, and Administrative Costs: Bio-Techne Corporation vs Evotec SE